ライフサイエンスコーパス: hairy cell leukemia

1 ents with either relapsed classic or variant hairy cell leukemia.

2 time the clinical and pathologic features of hairy cell leukemia.

3 1 in both leukemia and lymphoma, and BRAF in hairy cell leukemia.

4 ll known and revolutionized the treatment of hairy cell leukemia.

5 signaling important for the pathogenesis of hairy cell leukemia.

6 ted kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.

7 mphomas with villous lymphocytes (SLVLs) and hairy cell leukemia.

8 Only 2 of 40 deaths were attributed to hairy cell leukemia.

9 denosine analog, is clinically effective for hairy cell leukemia.

10 y profile when administered to patients with hairy cell leukemia.

11 BRAF V600E is the genetic lesion underlying hairy-cell leukemia.

12 tive in patients with relapsed or refractory hairy-cell leukemia.

13 ia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma

14 relapse-free survival times in patients with hairy cell leukemia, a disease that historically had bee

15 cally, this paper describes the frequency of hairy cell leukemia among all adult leukemias and charac

16 ons is helpful in the diagnosis of classical hairy cell leukemia and a number of histiocytic neoplasm

17 marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma.

18 Immunotoxin therapy is very effective in hairy cell leukemia and also has activity in other hemol

19 h an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V

20 cladribine) is effective in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.

21 lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predo

22 ate of complete remissions in drug-resistant hairy cell leukemia and has a lower response rate in ped

23 RITs have shown efficacy in refractory hairy cell leukemia and in some children with acute lymp

24 with reports of only a few cases of variant hairy cell leukemia and neurological disease associated

25 ladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also

26 The primary objective in multiply-relapsed hairy cell leukemia and variant (HCL/HCLv) was to determ

27 e been used to treat many diseases including hairy-cell leukemia and hepatitis B and C and have also

28 CldAdo), which is the drug of choice against hairy-cell leukemia and other neoplasms, from 2'-deoxygu

29 ancies including cutaneous T-cell lymphomas, hairy cell leukemia, and diffuse large B-cell lymphomas.

30 The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature c

31 The description of hairy cell leukemia as a specific clinical entity was pu

32 issions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias w

33 HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with

34 V600E-expressing human primary melanoma and hairy cell leukemia cells.

35 B-Raf kinase (BRAF mutations) are present in hairy-cell leukemia, cutaneous melanoma, thyroid carcino

36 The Hairy Cell Leukemia Foundation convened an international

37 n bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorod

38 s, 28 low grade B-cell lymphomas, 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.

39 V600E mutation was reported in all cases of hairy cell leukemia (HCL) but not in other peripheral B-

40 BRAFV600E mutation was recently detected in hairy cell leukemia (HCL) by whole exome sequencing.

41 tic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle

42 Hairy cell leukemia (HCL) derives from a mature B cell a

43 has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years.

44 The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of

45 Hairy cell leukemia (HCL) is a chronic B-cell leukemia n

46 Hairy cell leukemia (HCL) is a chronic lymphoproliferati

47 Hairy cell leukemia (HCL) is a chronic mature B-cell neo

48 Hairy cell leukemia (HCL) is a distinct clinicopathologi

49 Hairy cell leukemia (HCL) is a distinct clinicopathologi

50 Hairy cell leukemia (HCL) is a rare B-cell malignancy, a

51 Hairy cell leukemia (HCL) is a rare, indolent B-cell dis

52 Hairy cell leukemia (HCL) is an indolent B-cell neoplasm

53 Hairy cell leukemia (HCL) is an uncommon, indolent, chro

54 Hairy cell leukemia (HCL) is characterized by underexpre

55 Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic

56 Hairy cell leukemia (HCL) is marked by near 100% mutatio

57 One hairy cell leukemia (HCL) patient achieved a complete re

58 Hairy cell leukemia (HCL) responds very well to frontlin

59 Hairy cell leukemia (HCL) shows unique clinicopathologic

60 iral oncogene homolog B1 (BRAF) mutations in hairy cell leukemia (HCL) subsets, demonstrating that BR

61 To compare hairy cell leukemia (HCL) with chronic lymphocytic leuke

62 produce high response rates in patients with hairy cell leukemia (HCL), a significant number of patie

63 ), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lympho

64 ch as chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), are associated with myelosupp

65 target on B-cell malignancies, particularly hairy cell leukemia (HCL), but its soluble extracellular

66 sions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse ra

67 These included Hodgkin's disease (HD), hairy cell leukemia (HCL), non-Hodgkin's lymphoma (NHL),

68 e (BRAF V600E) is the key driver mutation in hairy cell leukemia (HCL), suggesting opportunities for

69 However, in hairy cell leukemia (HCL), these processes are particula

70 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory s

71 ious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).

72 recently described as a molecular marker of hairy cell leukemia (HCL).

73 duces protracted remissions in patients with hairy cell leukemia (HCL).

74 accepted as the agent of choice in treating hairy cell leukemia (HCL).

75 nd also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

76 tibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL).

77 600E is the key oncogenic driver mutation in hairy cell leukemia (HCL).

78 ates when used as first-line monotherapy for hairy cell leukemia (HCL); however, patients continue to

79 low-grade follicular lymphoma (FL; n = 44), hairy cell leukemia (HCL; n = 15), and reactive lymphoid

80 Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell can

81 ity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies h

82 ibine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv).

83 Hairy cell leukemia is a chronic B-cell disorder that fo

84 Hairy cell leukemia is an indolent, chronic B-cell lymph

85 Hairy cell leukemia is an uncommon hematologic malignanc

86 Although hairy cell leukemia is uniquely sensitive to interferon-

87 , an immunotoxin with impressive activity in hairy cell leukemia, is in phase II trials in CLL as wel

88 N-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago.

89 al blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic

90 glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 1

91 lymphoma, CLL, acute lymphoblastic leukemia, hairy cell leukemia, non-Hodgkin lymphoma (including rit

92 splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections.

93 Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerg

94 Treatment of hairy cell leukemia should be considered for symptomatic

95 Immunophenotypic features in classic hairy cell leukemia show that the leukemic cells express

96 entostatin is a highly effective regimen for hairy cell leukemia that produces durable complete respo

97 BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment wi

98 Hairy-cell leukemia that is resistant to treatment with

99 induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with

100 utcome of young patients with a diagnosis of hairy cell leukemia treated with cladribine.

101 Hairy cell leukemia variant (HCLv) presents with high di

102 isms driving variant and IGHV4-34-expressing hairy-cell leukemias, we performed whole-exome sequencin

103 A total of 358 patients with hairy cell leukemia were treated with cladribine at 0.08

104 d many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can

105 d many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be

106 notoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein resp

107 ts profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and